Abstract
Mammalian MAPK cascades are essential for cellular signaling in response to mitogenic signals and stress-stimuli to regulate proliferation, differentiation and apoptosis. The three major MAPK cascades, ERK1/2-, JNK- and p38, maintain signaling specificity by scaffolding proteins and by specific docking interactions between pathway components. The structures mediating these interactions include the domain of versatile docking (DVD) responsible for MAP3K-MAP2K-interaction and the common docking (CD)-domain and the ED (glutamate/aspartate)-site of MAPKs together with the various docking (D) motifs in MAP2Ks, MAPK substrates and MAPKphosphatases. Several of these interactions have been studied in great detail. First approaches to use this knowledge to develop peptides that specifically inhibit MAPK signaling in disease models have been reported. It becomes obvious that specificity of peptides competing with kinase-docking is comparable to or even superior to small molecule ATP-competitive inhibitors. In addition to specifically targeting protein-protein interactions, the ultimate efficacy of these peptide inhibitors in vivo also depends on their delivery, stability and toxicity in living cells and in the whole organism.
Keywords: DVD, CD domain, DEF domain, KIM domain, protein kinase, protein phosphatase, transcription factor, protein phosphorylation
Current Pharmaceutical Design
Title: Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Volume: 15 Issue: 21
Author(s): Matthias Gaestel and Michael Kracht
Affiliation:
Keywords: DVD, CD domain, DEF domain, KIM domain, protein kinase, protein phosphatase, transcription factor, protein phosphorylation
Abstract: Mammalian MAPK cascades are essential for cellular signaling in response to mitogenic signals and stress-stimuli to regulate proliferation, differentiation and apoptosis. The three major MAPK cascades, ERK1/2-, JNK- and p38, maintain signaling specificity by scaffolding proteins and by specific docking interactions between pathway components. The structures mediating these interactions include the domain of versatile docking (DVD) responsible for MAP3K-MAP2K-interaction and the common docking (CD)-domain and the ED (glutamate/aspartate)-site of MAPKs together with the various docking (D) motifs in MAP2Ks, MAPK substrates and MAPKphosphatases. Several of these interactions have been studied in great detail. First approaches to use this knowledge to develop peptides that specifically inhibit MAPK signaling in disease models have been reported. It becomes obvious that specificity of peptides competing with kinase-docking is comparable to or even superior to small molecule ATP-competitive inhibitors. In addition to specifically targeting protein-protein interactions, the ultimate efficacy of these peptide inhibitors in vivo also depends on their delivery, stability and toxicity in living cells and in the whole organism.
Export Options
About this article
Cite this article as:
Gaestel Matthias and Kracht Michael, Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades, Current Pharmaceutical Design 2009; 15 (21) . https://dx.doi.org/10.2174/138161209788682299
DOI https://dx.doi.org/10.2174/138161209788682299 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Necroptosis: Who Knew There were so Many Interesting Ways to Die?
CNS & Neurological Disorders - Drug Targets Cardiovascular Proteomics
Current Proteomics B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Therapeutic Approaches in Vascular Repair Induced by Adult Bone Marrow Cells and Circulating Progenitor Endothelial Cells
Current Pharmaceutical Design The Impact of Hypertension as a Road to Heart Failure with Preserved Ejection Fraction: Diagnostic Value of Two-Dimensional Speckle Tracking Echocardiography for the Early Impairment of Left Atrial-Left Ventricular-Arterial Coupling
Current Hypertension Reviews MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Endoplasmic Reticulum Stress Inhibition Enhances Liver Tolerance to Ischemia/Reperfusion
Current Medicinal Chemistry A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents
Current Clinical Pharmacology The Future of Collateral Artery Research
Current Cardiology Reviews